论文部分内容阅读
目的:评价重组人血管内皮抑制素与含铂化疗方案联合治疗晚期非小细胞肺癌临床疗效和不良反应。方法:试验组和对照组分别为21例和25例晚期非小细胞肺癌患者。试验组给予重组人血管内皮抑制素与含铂化疗方案联合治疗,对照组给予含铂方案化疗。观察两组近期有效率、疾病控制率、中位疾病无进展生存期、中位总生存期、1年生存率、治疗前后生活质量改善情况及不良反应。结果:试验组和对照组近期有效率、疾病控制率和中位疾病无进展生存期分别为28.57%、80.95%、5.0个月和24.00%、52.00%、4.0个月;中位总生存期和1年生存率分别为12.0个月、61.90%和9.0个月、44.00%,其中两组疾病控制率差异有统计学意义(P<0.05);生活质量改善率分别为85.71%和60.00%,主要不良反应为骨髓抑制和消化道反应。结论:重组人血管内皮抑制素与含铂化疗方案联合用于晚期非小细胞肺癌疾病控制率较好,有提高远期疗效和改善生活质量的趋势,不良反应可耐受。
Objective: To evaluate the clinical efficacy and adverse reactions of recombinant human endostatin combined with platinum-containing chemotherapy in the treatment of advanced non-small cell lung cancer. Methods: The experimental group and the control group were 21 cases and 25 cases of advanced non-small cell lung cancer patients. The experimental group was given recombinant human endostatin and platinum-containing chemotherapy combined treatment, the control group was given platinum-containing chemotherapy. The two groups were observed the recent efficiency, disease control rate, median disease progression-free survival, median overall survival, 1-year survival rate, quality of life before and after treatment to improve the situation and adverse reactions. Results: There were 28.57%, 80.95%, 5.0% and 24.00%, 52.00% and 4.0 months in trial group and control group respectively. The median effective rate and median survival time were The 1-year survival rates were 12.0 months, 61.90%, 9.0 months, and 44.00%, respectively. The difference in disease control rates between the two groups was statistically significant (P <0.05); the quality of life improvement rates were 85.71% and 60.00% Adverse reactions to myelosuppression and gastrointestinal reactions. Conclusion: The combination of recombinant human endostatin and platinum-containing chemotherapy regimen for the treatment of advanced non-small cell lung cancer has good control rate, long-term efficacy and quality of life improvement. Adverse reactions are tolerable.